Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma.
Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R, Aoki M, Imafuku K, Okuhira H, Wada N, Irie H, Hidaka T, Hashimoto A, Aiba S.
Fujimura T, et al. Among authors: hidaka t.
Front Oncol. 2018 Nov 19;8:530. doi: 10.3389/fonc.2018.00530. eCollection 2018.
Front Oncol. 2018.
PMID: 30510916
Free PMC article.